vs

Side-by-side financial comparison of Americas Gold & Silver Corp (USAS) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $19.1M, roughly 1.4× Americas Gold & Silver Corp). Zymeworks Inc. runs the higher net margin — -71.0% vs -82.3%, a 11.3% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -28.0%). Zymeworks Inc. produced more free cash flow last quarter ($-31.8M vs $-41.3M).

Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

USAS vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.4× larger
ZYME
$27.6M
$19.1M
USAS
Growing faster (revenue YoY)
ZYME
ZYME
+100.6% gap
ZYME
72.6%
-28.0%
USAS
Higher net margin
ZYME
ZYME
11.3% more per $
ZYME
-71.0%
-82.3%
USAS
More free cash flow
ZYME
ZYME
$9.5M more FCF
ZYME
$-31.8M
$-41.3M
USAS

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
USAS
USAS
ZYME
ZYME
Revenue
$19.1M
$27.6M
Net Profit
$-15.7M
$-19.6M
Gross Margin
34.2%
Operating Margin
-80.1%
Net Margin
-82.3%
-71.0%
Revenue YoY
-28.0%
72.6%
Net Profit YoY
2.8%
34.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
USAS
USAS
ZYME
ZYME
Q3 25
$19.1M
$27.6M
Q2 25
$48.7M
Q1 25
$27.1M
Q4 24
$31.0M
Q3 24
$26.5M
$16.0M
Q2 24
$19.2M
Q1 24
$10.0M
Net Profit
USAS
USAS
ZYME
ZYME
Q3 25
$-15.7M
$-19.6M
Q2 25
$2.3M
Q1 25
$-22.6M
Q4 24
$-23.5M
Q3 24
$-16.2M
$-29.9M
Q2 24
$-37.7M
Q1 24
$-31.7M
Gross Margin
USAS
USAS
ZYME
ZYME
Q3 25
34.2%
Q2 25
Q1 25
Q4 24
Q3 24
23.6%
Q2 24
Q1 24
Operating Margin
USAS
USAS
ZYME
ZYME
Q3 25
-80.1%
Q2 25
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-213.8%
Q2 24
-222.9%
Q1 24
-376.9%
Net Margin
USAS
USAS
ZYME
ZYME
Q3 25
-82.3%
-71.0%
Q2 25
4.8%
Q1 25
-83.5%
Q4 24
-75.8%
Q3 24
-60.9%
-186.6%
Q2 24
-195.8%
Q1 24
-315.6%
EPS (diluted)
USAS
USAS
ZYME
ZYME
Q3 25
$-0.26
Q2 25
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
USAS
USAS
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$39.1M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$50.2M
$320.1M
Total Assets
$234.7M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
USAS
USAS
ZYME
ZYME
Q3 25
$39.1M
$64.8M
Q2 25
$98.3M
Q1 25
$76.2M
Q4 24
$66.1M
Q3 24
$122.4M
Q2 24
$71.0M
Q1 24
$114.8M
Stockholders' Equity
USAS
USAS
ZYME
ZYME
Q3 25
$50.2M
$320.1M
Q2 25
$334.5M
Q1 25
$325.0M
Q4 24
$338.8M
Q3 24
$53.1M
$367.0M
Q2 24
$406.2M
Q1 24
$438.0M
Total Assets
USAS
USAS
ZYME
ZYME
Q3 25
$234.7M
$397.3M
Q2 25
$408.4M
Q1 25
$425.5M
Q4 24
$463.1M
Q3 24
$487.2M
Q2 24
$515.6M
Q1 24
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
USAS
USAS
ZYME
ZYME
Operating Cash FlowLast quarter
$-12.5M
$-31.4M
Free Cash FlowOCF − Capex
$-41.3M
$-31.8M
FCF MarginFCF / Revenue
-216.5%
-115.2%
Capex IntensityCapex / Revenue
150.8%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
USAS
USAS
ZYME
ZYME
Q3 25
$-12.5M
$-31.4M
Q2 25
$12.1M
Q1 25
$-3.4M
Q4 24
$-41.5M
Q3 24
$2.4M
$-5.9M
Q2 24
$-25.0M
Q1 24
$-37.7M
Free Cash Flow
USAS
USAS
ZYME
ZYME
Q3 25
$-41.3M
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-11.2M
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
USAS
USAS
ZYME
ZYME
Q3 25
-216.5%
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.2%
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
USAS
USAS
ZYME
ZYME
Q3 25
150.8%
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
51.2%
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
USAS
USAS
ZYME
ZYME
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons